The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2017 | Are prognostic factors the key to precision medicine in CLL?
William Wierda, MD, PhD from MD Anderson Cancer Center, Houston, TX discusses the value of prognostic markers in chronic lymphocytic leukemia (CLL). Prof. Weirda provides an overview of his presentation on precision medicine in CLL, describing how prognostic factors can be used to manage patients and to help predict clinical outcomes. Prof. Weirda details examples of genetic mutations which can act as prognostic markers and discusses how community physicians can test for these in the clinic. This interview was recorded the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 held in New York, NY.
